NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach